Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Burning Rock Biotech (BNR) EBIT: 2019-2025

Historic EBIT for Burning Rock Biotech (BNR) over the last 7 years, with Sep 2025 value amounting to $20.7 million.

  • Burning Rock Biotech's EBIT rose 483.73% to $20.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$30.5 million, marking a year-over-year decrease of 118.34%. This contributed to the annual value of -$49.0 million for FY2024, which is 48.04% up from last year.
  • According to the latest figures from Q3 2025, Burning Rock Biotech's EBIT is $20.7 million, which was up 184.05% from -$24.6 million recorded in Q2 2025.
  • Burning Rock Biotech's EBIT's 5-year high stood at $620.8 million during Q4 2022, with a 5-year trough of -$234.6 million in Q3 2022.
  • In the last 3 years, Burning Rock Biotech's EBIT had a median value of -$24.6 million in 2025 and averaged -$18.7 million.
  • Over the last 5 years, Burning Rock Biotech's EBIT had its largest YoY gain of 1,632.62% in 2022, and its largest YoY loss of 780.07% in 2022.
  • Quarterly analysis of 5 years shows Burning Rock Biotech's EBIT stood at -$40.5 million in 2021, then soared by 1,632.62% to $620.8 million in 2022, then crashed by 34.16% to $408.7 million in 2023, then slumped by 102.79% to -$11.4 million in 2024, then skyrocketed by 483.73% to $20.7 million in 2025.
  • Its last three reported values are $20.7 million in Q3 2025, -$24.6 million for Q2 2025, and -$15.2 million during Q1 2025.